Michael Wang, MD, discusses the potential role for the next-generation Bruton's tyrosine kinase inhibitor zanubrutinib compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma.
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the potential role for the next-generation Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma (MCL).
Zanubrutinib is the newest BTK inhibitor to appear in the treatment landscape for patients with MCL, but it does not have significant follow-up time yet, Wang says. There are many interesting points for the role of zanubrutinib in MCL, and it is an active agent, according to Wang. This agent receivedpriority review from the FDA in August 2019 for the treatment of patients with MCLwho have received at least 1 prior treatment.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More